Original article

Quercetin suppresses cellular migration and invasion in human head and neck squamous cell carcinoma (HNSCC)

Chien-Yi Chan, Chia-Hsien Lien, Ming-Fen Lee, Chun-Yin Huang*

Department of Nutrition, China Medical University, Taichung 404, Taiwan
Department of Nutrition and Health Sciences, Chang Jung Christian University, Tainan 711, Taiwan

Received 7th of June 2016    Accepted 24th of June 2016

© Author(s) 2016. This article is published with open access by China Medical University

Keywords:
HNSCC; Quercetin

ABSTRACT

Head and neck squamous cell carcinoma (HNSCC) with aberrant epidermal growth factor receptor (EGFR) signaling is often associated with a poor prognosis and a low survival rate. Hence, efficient inhibition of the EGFR signaling-mediated malignancy would improve survival rate. In a previous study, we demonstrated that quercetin appears to be a potent anti-tumorigenic agent through its inhibition of the EGFR/Akt pathway in oral cancer, but its anti-metastatic potential in HNSCC remains unclear [1]. Here, we have hypothesized that quercetin might be effective in metastatic inhibition in EGFR-overexpressing HNSCC cells. Quercetin treatment with 10 μM (half concentration of IC50) suppressed cell migration and invasion in EGFR-overexpressing HSC-3 and FaDu HNSCC cells. Quercetin also inhibited the colony growth of HSC-3 cells embedded in a Matrigel matrix. Among matrix metalloproteinases (MMPs), the secreted gelatinases MMP-2 and MMP-9 are responsible for the degradation of gelatin in the extracellular matrix and type IV collagen in the basement membrane; and this degradation event is crucial for the migration from the origin and the invasion into the bone in HNSCC. Quercetin (10 μM) treatment also suppressed the expression and proteolytic activity of MMP-2 and MMP-9. Taken together, our data indicate that quercetin is an effective anti-cancer agent against MMP-2- and MMP-9-mediated metastasis in EGFR-overexpressing HNSCC.

1. Introduction

Epidermal growth factor (EGF) receptor (EGFR) gene is frequently amplified in head and neck squamous cell carcinoma (HNSCC) [2]. Increased expression of EGFR and its ligand are often associated with poor clinical outcome—that is, high recurrence and low survival rates [3-5]. EGFR activation is often implicated in malignant phenotypes of cancer cells: increased survival, anti-apoptosis, angiogenesis, and metastatic potential through signal transduction pathways, such as phosphoinositide 3-kinase (PI3K)/Akt and RAS/extracellular signal-regulated kinases (ERK)[6, 7]. Matrix metalloproteinase (MMP) family are involved in the integrity regulation of the extracellular microenvironment [8]. Inhibition of the PI3K/Akt signal transduction pathway may result in the reduction of MMP proteins, indicating an important role of the EGFR/Akt/MMP signal axis in controlling the metastatic potential of cancers.

MMP family members, including MMP-2 and MMP-9, play a crucial role in cancer malignancy and metastasis [9-11]. Higher expression levels of MMP-2 and MMP-9 have been found in oral cancer cells when compared to their normal mucosal counterparts [12-14]. Clinically, drugs available for oral cancer patients are mainly designed to target EGFR [15-17]; however, mutations of the EGFR downstream effectors and resistance to said drugs have been reported in some patients [5]. Therefore, to improve therapeutic efficacy, new anti-cancer agents should be considered accordingly.

Quercetin (3, 3’, 4’, 5, 7-pentahydroxyflavone), a major dietary flavonol, exists naturally in a wide range of fruits, vegetables, and their products, including onions, apples, and red wine [18]. In addition to its antioxidant, anti-inflammatory, and anti-proliferative and proapoptotic properties [18], quercetin has also been widely investigated for its potential to inhibit both cellular migration and the invasion of cancer cells, including glioblastoma [19, 20], melanoma [21], prostate cancer [22], breast cancer [23, 24], and oral cancer cells [25, 26]. Mechanistically, quercetin may inhibit cellular migration and invasion through the deactivation of MMP-2 and/or MMP-9 [20, 23, 24, 26]; however, evidence regarding the anti-metastatic efficacy of quercetin in invasive HNSCC is still limited. Therefore, the current study is aimed at investigating the effects of quercetin on the invasiveness of aggressive HNSCC cells.

*Corresponding author. Department of Nutrition, China Medical University, No. 91 Hsueh-Shih Road, Taichung 404, Taiwan.
E-mail address: chuang@mail.cmu.edu.tw (C.-Y. Huang).
In a previous study, we demonstrated that quercetin is a poten
t anti-growth agent in EGFR-overexpressing oral cancer
cells, where quercetin inhibits cell growth and induces apo
tosis through modulation of the EGFR/Akt/FOXO1 axis [1]. In
this current study, we investigated the inhibitory effect of quercetin
on cellular migration and invasion in human HNSCC cell lines
with lymph node metastasis [27, 28], and we further identified the
suppressive role of quercetin in MMP-2 and MMP-9-mediated
invasion.

2. Materials and methods

2.1. Reagents and antibodies

All chemicals including quercetin were purchased from Sigma (St.
Louis, MO) unless specified otherwise. Antibodies for MMP-2
and MMP-9 were purchased from Abcam (Burlingame, CA).
Polyvinylidenedifluoride (PVDF) membranes and enhanced
chemiluminescence (ECL) detection reagents were bought from
Perkin Elmer Life Sciences, Inc. (Waltham, MA).

2.2. Cell culture and treatment

HSC-3 and FaDu human HNSCC cells were kindly gifted to us by
Drs. Tzong-Ming Shieh and Tzong-Der Way at China
Medical University (Taichung, Taiwan), respectively. FaDu and
HSC-3 cells were maintained in Dulbecco’s Modified Eagle Me-
dium (DMEM) and DMEM-F12 (Invitrogen), respectively, sup-
plemented with 10% fetal bovine serum (FBS) and 1% antibiotic-
anti-biotic (Gibco). Cells were maintained in an incubator
supplemented with 5% CO2 at 37°C.

2.3. Western blot analysis [1]

Cells were washed with cold PBS and lysed in a RIPA buffer
containing 150 mM NaCl, 10 mM Tris (pH 7.2), 0.1% sodium do-
decyl sulfate, 1% Triton X-100, 1% deoxycholate, 5 mM EDTA,
and protease/phosphatase inhibitors. Protein concentration was
determined by BCA protein assay, and denatured proteins were
separated in 10% sodium dodecyl sulfate-polyacrylamide gels
(SDS-PAGE) and transferred onto PVDF membranes. Nonspe-
cific binding was blocked with 5% milk in a TBST buffer (20
mM Tris–HCl (pH 7.5), 200 mM NaCl, 5 mM CaCl2, and 0.02%
M

2.4. Wound-healing assay

HSC-3 and FaDu cells (3 × 10⁴ cells) were seeded onto a Culture-
insert 2 well (ibidi, Munich, Germany) which was placed onto a
12-well plate. After 24 h of attachment, the Culture-insert 2 well
was removed and cells were incubated in a medium containing
various concentration of quercetin (0-10 μM). Wound healing
was observed and photographed every 2 hours under a micro-
scope with 200× magnification.

2.5. Matrigel invasion assay [29]

Matrigel inserts for 24-well chambers were obtained from
BD Biosciences (Bedford, MA) and used according to the manu-
facturer’s protocol. HSC-3 cell suspensions (3 × 10⁴ cells) were
added to the upper chamber, with or without 10 μM of quercetin
in a serum-free growth medium, and a chemoattractant (10%
FBS-containing medium) was added to the lower chamber. After
48 h of incubation in a 37°C, 5% CO2 incubator, the non-invading
cells from the upper chamber were removed using cotton swabs,
and the cells on the lower surface were fixed with 100% metha-
nol, stained (Giesma in 20% ethanol), and counted. Cell invasion
was photographed under 400× magnification. The invaded cells
were counted in five randomly selected microscopic fields (200×
magnification). Error bars in Fig. 1B represent the variation of
the cell numbers between the selected fields.

2.6. Gelatin zymography [29]

HSC-3 and FaDu cells (1 × 10⁴ cells) were incubated in a growth
medium supplemented with quercetin for 24 h. The media were
then collected and separated on 8% SDS-PAGE containing 0.1%
(w/v) gelatin. After separation, the gels were washed in a renatur-
ing buffer containing 2.5% Triton X-100 at room temperature for
30 min and then incubated in a developing buffer containing 50
mM Tris–HCl (pH 7), 200 mM NaCl, 5 mM CaCl₂, and 0.02%
Brij 35 at 37°C for 16 h. Lastly, the gels were stained with 0.2%
Coomassie blue and destained in 50% methanol, 10% acetic acid,
and 40% water. The proteolytic activity of the indicated MMPs
was detected as a clear band against a dark blue background.

2.7. Colony formation in a 3D Matrigel model

A Lab-Tek® II Chamber slide (Thermo Fisher Scientific, Waltham,
MA) was pre-coated with a 70 μl Matrigel matrix and polymer-
ization was allowed for in a 37°C incubator for 10 to 15 minutes.
Cells in the growth medium mixed with the indicated concentra-
tion 0 or 10 μM of quercetin and 2% Matrigel matrix were trans-
ferred onto the chamber slide. Once the gel was polymerized,
cells were allowed to grow with the changing media every other
day for 6 days. Colony formation was photographed under 200×
magnification.

2.8. Quantitative real-time polymerase chain reaction (qPCR)

Cellular RNA was extracted using an RNaseasy Mini Kit (Qiagen,
Valencia, CA) according to the manufacturer’s instructions, and
reverse-transcribed into cDNA using the iScript cDNA Kit (Bio-
Rad, Hercules, CA) again according to the manufacturer’s instruc-
tions. Then, quantitative real time PCR was carried out using the
Bio-Rad iQ SYBR Green Supermix (Bio-Rad, Hercules, CA)
with the MJ Mini™ Thermal Cycler equipped with Bio-Rad CFX
Manager software (Bio-Rad, Hercules, CA) [30]. The following
primers were used: human MMP-2, 5’-CATCAAGTTCGCCG-
GCATG-3’(F) and 5’-AACAGGTTCAGCTCCT-3’(R);
MMP-9, 5’-CTTCTTAGCGTGTTGACGAT-3’(F) and 5’-
TGCCGATCTCCTCATT-3’(R); 18S, 5’-GTCGTGAT-
GCGTTTAGATG-3’(F) and 5’-AGCTTATGACCGCACT-
TAC-3’(R).

2.9. Statistical analysis

Data are expressed as mean ± SD from at least three independent
experiments. Statistical significance was analyzed using Stu-
dent’s t test. Results were considered significantly different at p <
0.05.
3. Results

3.1. Quercetin inhibits cell migration, invasion, and colony growth in human HNSCC cells

Again, in a previous study, we demonstrated that EGFR-overexpressing oral cancer cells are sensitive to the growth-inhibitory effect of quercetin [1]. However, its anti-metastatic efficacy potential regarding EGFR-overexpressing HNSCC cells remains elusive and unclear. In the present study, we exposed two human HNSCC cell lines, HSC-3 and FaDu, to various concentrations (0 to 10 μM) of quercetin, quantities which are all much less than the IC50 (20 μM) of quercetin for HSC-3 cells [1].

Quercetin dose-dependently inhibited cellular migration in both HSC-3 and FaDu cells as evidenced by delayed wound-healing time (Fig. 1A). Further, administration of 10 μM of quercetin also significantly suppressed the ability of HSC-3 cells to invade through a Matrigel basement membrane (Fig. 1B). These results indicate that the metastatic HSC-3 and FaDu cell lines are in fact susceptible to quercetin. Indeed, quercetin supplementation for 6 days significantly suppressed HSC-3 colony formation in a 3D Matrigel model that mimics the physiological cell-cell and cell-extracellular matrix (ECM) interaction (Fig. 2). Taken together, these data support the possibility of quercetin as a potential anti-metastatic reagent in human HNSCC.

3.2. Quercetin modulates MMP-2 and MMP-9 activation

MMP-2 and MMP-9 are secreted gelatinases responsible for the degradation of gelatin in the ECM and type IV collagen in the basement membrane, and both are also implicated in the migration from the origin and the invasion into the bone in HNSCC [27]. With this in mind, we examined the effect of quercetin on the activation of MMP-2 and MMP-9. After 24 h of treatment, quercetin displayed inhibitory efficacy on the protein levels of both MMP-2 and MMP-9 (Fig. 3A). Low concentrations of quercetin (1-5 μM) had almost no effect on MMP-9 protein levels while high concentrations of quercetin (10-20 μM) potently suppressed MMP-9 protein levels; however, quercetin only mildly suppressed MMP-2 protein levels in a dose-dependent manner (Fig. 3A). The effect of quercetin on the proteolytic activity of MMP-9 and MMP-2 was in agreement with that of the protein expression level (Fig. 2).
Finally, we examined whether or not the observed reduction of MMP protein levels was due to decreased transcription. The qPCR data confirmed that the mRNA expression levels of both MMP-9 and MMP-2 were significantly reduced upon receiving 10 μM of quercetin treatment (Fig. 3C).

Taken as a whole, our results indicate that quercetin at a concentration of 10 μM potently inhibits cellular migration and invasion, at least in part, through the modulation of MMP-9 and MMP-2 activation in EGFR-overexpressing HNSCC.

4. Discussion

The deregulated EGFR signaling pathway associated with cancer malignancy is often found in HNSCC [31]. Again, we have demonstrated in a previous study that quercetin is a potent inhibitor of the EGFR/Pi3K/Akt pathway-mediated cell growth in the EGFR-overexpressing HSC-3 oral cancer cell line [1]. In the current study, we further identified that quercetin at a concentration of 10 μM also displays anti-metastatic potential as evidenced by the suppression of cellular migration, invasion, and colony formation in a 3D Matrigel model in EGFR-overexpressing HNSCC cells (Figs. 1-2). Our data suggest that HNSCC with EGFR overexpression seems quite sensitive to the anti-cancer efficacy of quercetin.

Aberrant EGFR signaling activation is correlated with the expression of MMPs including MMP-2 and MMP-9 [32]. MMP-2 and MMP-9 are highly implicated in cellular growth, migration, and invasion of HNSCC [32]; MMP-2 is significantly correlated with metastasis to lymph nodes while MMP-9 is involved in the control of tumor neovascularization [32]. Although MMP-9 is not highly expressed in HSC-3 cells [27], its expression is potently induced upon EGF stimulation and is responsible for EGF-mediated cellular invasion [33]. Thus, reagents targeting MMP-2 and MMP-9 may help suppress HNSCC metastasis. Here, we have demonstrated that quercetin (10 μM) significantly suppressed the transcriptional activation of MMP-2 and MMP-9 in both HSC-3 and FaDu cells (Fig. 3). These data indicate that quercetin may inhibit metastasis of EGFR-overexpressing HNSCC through the down-regulation of MMP-2 and MMP-9.

In summary, our data support the possibility of quercetin as an efficient anti-cancer agent in EGFR-overexpressing HNSCC. Quercetin efficiently inhibits the cellular migration and invasion of the HNSCC cell lines, HSC-3 and FaDu. In addition, quercetin also inhibits the colony formation of HSC-3 cells surrounded with Matrigel matrix. Our data show that the activation of gelatinase MMP-2 and MMP-9 was suppressed by quercetin administration. As illustrated in Fig. 4, quercetin may inhibit migration and invasion of the HNSCC cells, in part, through suppressing the expression of MMP-2 and MMP-9. Collectively, our data indicate quercetin is a potential alternative regimen for HNSCC patients carrying an aberrant EGFR signaling axis.

Acknowledgements

This work was supported by the grants, CMU97-303 (China Medical University) and NSC98-2320-B-039-021-MY3 (National
Quercetin

\[ \text{MMP-9} \]
\[ \text{MMP-2} \]

Migration & invasion in HNSCC cells

Fig.4 - Schematic model of anti-metastatic effect of quercetin in HNSCC.

Science Council), given to Chun-Yin Huang.

Open Access This article is distributed under terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided original author(s) and source are credited.

REFERENCES

[1] Huang CY, Chan CY, Chou IT, Lien CH, Hung HC, Lee MF. Quercetin induces growth arrest through activation of FOXO1 transcription factor in EGFR-overexpressing oral cancer cells. J Nutr Biochem 2013, 24(9): 1596-603.

[2] Sheu JJ, Hua CH, Wan L, Lin YJ, Lai MT, Tseng HC, et al. Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer research 2009, 69(6):2568-76.

[3] Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006, 24(24):4170-6.

[4] Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007, 25(16):2164-70.

[5] Ratulshy V, Astsaturov I, Burtlness BA, Golemis EA, Silverman JS. Targeting EGFR resistance networks in head and neck cancer. Cell Signal 2009, 21(8): 1255-68.

[6] Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 2009, 20(10): 851-5.

[7] Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003, 284(1): 31-53.

[8] Zhou QL, Yang CX, Liang H, Liu HZ, Wang HB, Liu Y, et al. Propofol reduces MMPs expression by inhibiting PI3K/AKT activity in human HepG2 cells. Biomedicine & pharmacotherapy = Biomedicine & pharmacotherapie 2013.

[9] Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. Journal of the National Cancer Institute 1997, 89(17): 1260-70.

[10] Culhaci N, Metin K, Copcu E, Dikicioglu E. Elevated expression of MMP-13 and TIMP-1 in head and neck squamous cell carcinomas may reflect increased tumor invasiveness. BMC cancer 2004, 4: 42.

[11] Komatsu K, Nakanishi Y, Nemoto N, Hori T, Sawada T, Kobayashi M. Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas. Brain tumor pathology 2004, 21(3):105-12.

[12] Johansson N, Airola K, Grenman R, Karinistemi AL, Saarialho-Kere U, Kahari VM. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 1997, 151(2): 499-508.

[13] Kawamata H, Nakashiro K, Uchida D, Harada K, Yoshida H, Sato M. Possible contribution of active MMP2 to lymph-node metastasis and secreted cathepsin L to bone invasion of newly established human oral-squamous-cancer cell lines. Int J Cancer 1997, 70(1): 120-7.

[14] Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T. Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker. Int J Cancer 2005, 116(3): 422-7.

[15] Burtlness B. The role of cetuximab in the treatment of squamous cell carcinoma of the head and neck. Expert Opin Biol Ther 2005, 5(8): 1085-93.

[16] Burtlness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005, 23(34): 8646-54.

[17] Dobelbower MC, Russo SM, Raisch KP, Seay LL, Clemons LK, Suter S, et al. Epidernal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-flourouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study. Anticancer Drugs 2006, 17(1): 95-102.

[18] Lamson DW, Brignall MS. Antioxidants and cancer, part 3: quercetin. Altern Med Rev 2000, 5(3): 196-208.

[19] Michaud-Levesque J, Bousquet-Gagnon N, Beliveau R. Quercetin abrogates IL-6/STAT3 signaling and inhibits glioblastoma cell line growth and migration. Exp Cell Res 2012, 318(9): 925-35.

[20] Pan HC, Jiang Q, Yu Y, Mei JP, Cui YK, Zhao WJ. Quercetin promotes cell apoptosis and inhibits the expression of MMP-9 and fibronectin via the AKT and ERK signalling pathways in human glioma cells. Neurochem Int 2015, 80: 60-71.

[21] Cao HH, Cheng CY, Su T, Fu QX, Guo H, Li T, et al. Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion. Mol Cancer 2015, 14: 103.

[22] Bhat FA, Sharmila G, Balakrishnan S, Arunkumar R, Elumalai P, Suganya S, et al. Quercetin reverses EGF-induced epithelial to mesenchymal transition and invasiveness in prostate cancer (PC-3) cell line via EGFR/PI3K/Akt pathway. J Nutr Biochem 2014, 25(11): 1132-9.

[23] Lin CW, Hou WC, Shen SC, Juan SH, Ko CH, Wang LM, et al. Quercetin inhibition of tumor invasion via suppressing PKC delta/ERK/AP-1-dependent matrix metalloproteinase-9 activation in breast carcinoma cells. Carcinogenesis 2008, 29(9): 1807-15.

[24] Seo HS, Ku JM, Choi HS, Choi YK, Woo JK, Kim M, et al. Quercetin induces caspase-dependent extrinsic apoptosis through inhibition of signal transducer and activator of transcription 3 signaling in...
HER2-overexpressing BT-474 breast cancer cells. Oncol Rep 2016.

[25] Chen SF, Nien S, Wu CH, Liu CL, Chang YC, Lin YS. Reappraisal of the anticancer efficacy of quercetin in oral cancer cells. J Chin Med Assoc 2013, 76(3): 146-52.

[26] Lai WW, Hsu SC, Chueh FS, Chen YY, Yang JS, Lin JP, et al. Quercetin inhibits migration and invasion of SAS human oral cancer cells through inhibition of NF-kappaB and matrix metalloproteinase-2/-9 signaling pathways. Anticancer Res 2013, 33(5):1941-50.

[27] Erdem NF, Carlson ER, Gerard DA, Ichiki AT. Characterization of 3 oral squamous cell carcinoma cell lines with different invasion and/or metastatic potentials. J Oral Maxillofac Surg 2007, 65(9): 1725-33.

[28] Rangan SR. A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer 1972, 29(1): 117-21.

[29] Huang CY, Chou YH, Hsieh NT, Chen HH, Lee MF. MED28 regulates MEK1-dependent cellular migration in human breast cancer cells. J Cell Physiol 2012, 227(12): 3820-7.

[30] Lee MF, Chan CY, Hung HC, Chou IT, Yee AS, Huang CY. N-acetylcysteine (NAC) inhibits cell growth by mediating the EGFR/Akt/HMG box-containing protein 1 (HBP1) signaling pathway in invasive oral cancer. Oral Oncol 2012.

[31] Kozaki K, Imoto I, Pimkhaotham A, Hasegawa S, Tsuda H, Omura K, et al. PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Sci 2006, 97(12): 1351-8.

[32] Lim SC. Expression of c-erbB receptors, MMPs and VEGF in head and neck squamous cell carcinoma. Biomed Pharmacother 2005, 59 Suppl 2: S366-9.

[33] Ohnishi Y, Lierger O, Attygalla M, Iizuka T, Kakudo K. Effects of epidermal growth factor on the invasion activity of the oral cancer cell lines HSC3 and SAS. Oral Oncol 2008, 44(12): 1155-9.